Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRY1 | Q16526 | 4/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.40 |
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246557 | 0.79 | PER2 (0.40) | CRY1CRY2PER2HTR5A | |
| SCHEMBL13622573 | 0.78 | CRY1 (0.45) | CRY1CRY2PER2HTR5A | |
| SCHEMBL8283804 | 0.76 | CRY1 (0.40) | CRY1CRY2PER2HTR5A | |
| SCHEMBL8253155 | 0.74 | — | — | |
| SCHEMBL8271463 | 0.73 | CRY1 (0.43) | CRY1CRY2PER2 | |
| SCHEMBL8249897 | 0.69 | PER2 (0.44) | CRY1CRY2PER2 | |
| SCHEMBL13122597 | 0.69 | CRY1 (0.33) | CRY1CRY2 | |
| SCHEMBL13622571 | 0.68 | CRY1 (0.47) | CRY1CRY2PER2HTR5A | |
| SCHEMBL8249780 | 0.68 | CRY1 (0.40) | CRY1CRY2PER2 | |
| SCHEMBL16297899 | 0.68 | CRY1 (0.40) | CRY1CRY2PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130628-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | CRY1 2678/4885CRY2 3659/4885PER2 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.